Overview

• Over 100 Korean companies officially registered for BIO USA with total Korean participation nearing 400 firms, marking a record presence on the global stage.
• Samsung Biologics centered its 167-sqm booth on showcasing its 784,000-liter biologics capacity, newly launched ADC service and organoid-based drug screening platform.
• The 1,800-sqm Korea Pavilion was the largest national exhibit, housing 51 companies in investor sessions and meetings for licensing and co-development.
• Major developers like Celltrion and SK Biopharmaceuticals used the event to pitch next-generation ADCs, Alzheimer’s candidates and epilepsy treatments to global partners.
• Chinese rival WuXi Biologics staged a boycott in protest of the U.S. Biosecure Act, underscoring geopolitical tensions over biotech security.